Biocytogen and Merck to advance antibody-conjugated lipid-based delivery solutions

Biocytogen will provide proprietary, fully human antibodies derived from its RenMice platform for evaluation in Merck’s antibody-conjugated LNP services

Gilead Sciences breaks ground on new manufacturing and technical development site in US

New Bay Area building marks significant progress as part of $32 billion US investment projected to create $43 billion in economic value

Argo Biopharma inks $5.2 billion deal with Novartis for novel molecules for cardiovascular diseases

Argo will receive an upfront payment of $160 million, an option for Profit & Loss split across multiple geographies and potential near-term equity

Strides partners with Kenox to expand nasal spray portfolio for US market

Kenox to provide formulation and development expertise in orally inhaled and nasal drug products

MedTech Expo 2025: ICMR licenses nine technologies to 17 industry partners

These licenses are given in areas of infectious disease diagnostics, immunodiagnostics, and vaccine development

Zydus and Synthon ink licensing and supply agreement for Ozanimod Capsules for US market

Under the terms of this agreement, Synthon will be responsible for obtaining final regulatory approval for its Ozanimod Capsules product

AstraZeneca’s Baxdrostat proves effective in in Phase III trial for hard-to-control hypertension

The medicine was well tolerated, with no unexpected safety issue

Resolution Therapeutics doses first patient in phase I/II Emerald study of RTX001 for end-stage liver disease

RTX001 represents a groundbreaking advance in the treatment of end-stage liver disease, offering new hope for patients with limited options

Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis

Aarti Pharmalabs inaugurates phase 1 of greenfield manufacturing facility

Phase 1 has a total reactor capacity of 440 kL with 63 reactors